Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
This trial is active, not recruiting.
|Treatments||grazoprevir, mk-3682, elbasvir, ruzasvir, mk-3682b, ribavirin|
|Sponsor||Merck Sharp & Dohme Corp.|
|Start date||January 2015|
|End date||September 2016|
|Trial size||465 participants|
|Trial identifier||NCT02332707, 2014-003304-73, 3682-011|
This is a randomized, three-part, open-label trial of grazoprevir (MK-5172) (100 mg) and MK-3682 (300 mg or 450 mg), with either elbasvir (MK-8742) (50 mg) or ruzasvir (MK-8408) (60 mg), and with or without ribavirin (RBV), in treatment-naïve (TN) and treatment-experienced (TE) cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) participants with chronic HCV genotype (GT) 1 or GT2 infection. Part A will consist of 8 arms to evaluate the safety of dose combinations. In Part B, participants will take 2 MK-3682B fixed dose combination (FDC) tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.) RBV (200 mg capsules; weight-based dosing). Participants who relapse following completion of therapy in Part A will be offered the option of retreatment with 16 weeks of MK-3682B with RBV in Part C (data obtained from Part C will not be used in the analysis of outcome measures).
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12)
time frame: Up to 28 weeks
Number of participants experiencing an adverse event (AE)
time frame: Up to 18 weeks
Number of participants who had study drug discontinued due to an AE
time frame: Up to 16 weeks
Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR24)
time frame: Up to 40 weeks
Male or female participants at least 18 years old.
Inclusion Criteria: Parts A and B: - Previously untreated chronic HCV GT1 or GT2 with no evidence of non-typeable or mixed genotype infection - Has HCV ribonucleic acid (RNA) >= 10,000 IU/mL in peripheral blood at the time of screening - Has cirrhosis of the liver (Part B only) or is non-cirrhotic (Part A and B) - Is HCV treatment naïve (defined as no prior exposure to any interferon, ribavirin, or other approved or experimental HCV-specific direct-acting antiviral agent) - Is of non childbearing potential or agrees to avoid becoming pregnant or impregnating a partner beginning at least 2 weeks prior to administration of the initial dose of study drug and either for 14 days after the last dose of study drug if not taking RBV or for 6 months after the last dose of study drug if taking RBV (or longer if dictated by local regulations). If not abstinent from heterosexual activity, participants in Part A must use 2 acceptable forms of barrier contraception whereas participants in Part B must use 2 acceptable forms of contraception which may include oral contraceptives Part B only: - If coinfected with human immunodeficiency virus (HIV) is not currently on antiretroviral therapy (ART) and has no plans to initiate ART treatment while participating in this study OR has well controlled HIV on ART (the ART regimen must contain only the following antiretroviral medications: tenofovir, abacavir, lamivudine, emtricitabine, raltegravir, dolutegravir, and rilpivirine with no dose modifications or changes in drugs in the 4 weeks prior to study entry [Day 1]) - Has at least one viable antiretroviral regimen alternative beyond their current regimen in the event of HIV virologic failure and the development of anti-retroviral drug resistance Exclusion Criteria: Parts A, B, and C (unless noted otherwise): - Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease - For cirrhotics (Part B only), participants who are Child-Pugh Class B or C or who have a Pugh-Turcotte (CPT) score >5, must be excluded - Is coinfected with hepatitis B virus - Is coinfected with HIV (Part A only) - If coinfected with HIV (Part B only), has a history of opportunistic infection in the preceding 6 months prior to screening - Has a history of malignancy <=5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy - Has cirrhosis and has had liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC - Has clinically-relevant drug or alcohol abuse within 12 months of screening - Pregnant or breast-feeding, or expecting to conceive or donate eggs from at least 2 weeks prior to Day 1 and 90 days after the last dose of study medication, or longer if dictated by local regulations - Has any of the following conditions: - organ transplants (including hematopoietic stem cell transplants) other than cornea and hair - poor venous access that precludes routine peripheral blood sampling required for this trial - has a history of gastric surgery (e.g., stapling, bypass) or history of malabsorption disorders (e.g., celiac sprue disease) - current or history of any clinically significant cardiac abnormalities/dysfunction, including but not limited to: angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia, uncontrolled hypertension, a history of use of antianginal or anti-arrhythmic agents for cardiac conditions, prolonged ECG QTc interval (>470 ms for males or >480 ms for females by the Fridericia formula) at the screening visit, personal or family history of Torsade de pointes - has chronic pulmonary disease, including but not limited to: clinically significant chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis - has central nervous system (CNS) trauma requiring intubation, intracranial pressure monitoring, brain meningeal or skull surgery, or resulting in seizure, coma, permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF) leak. Prior brain hemorrhage and/or intracranial aneurysms (whether adequately repaired or not) - has a current, or history of, seizure disorder unless seizure was >10 years ago, a single isolated event, no history of or current use of anti-seizure medications prescribed, and a normal neurological examination is documented in trial files within 6 months of Day 1 - Has a history of stroke or transient ischemic attack - Has a history of a medical/surgical condition that resulted in hospitalization within the 3 months prior to enrollment, other than for minor elective procedures - Has a medical/surgical conditions that may result in a need for hospitalization during the period of the study - Has any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids, TNF antagonists, or other immunosuppressant drugs during the course of the trial - has any condition, prestudy laboratory or ECG abnormality or history of any illness, which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the subject - has a life-threatening SAE during the screening period - has evidence of history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, alcoholic liver disease, and autoimmune hepatitis Parts B and C only: is a male whose female partner(s) is/are pregnant
|Official title||A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection|
|Description||In Part A, study therapy will be administered as separate products, each taken q.d. by mouth. In Part B and Part C, participants will take 2 MK-3682B FDC tablets q.d. by mouth; each MK-3682B FDC tablet contains grazoprevir 50 mg + MK-3682 225 mg + ruzasvir 30 mg.|
Call for more information